Sionna Therapeutics initiated with a Buy at Stifel

Stifel analyst Paul Matteis initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $32 price target Sionna is a biotech company focused on developing novel treatment regimens for cystic fibrosis, working on a novel mechanism-of-action in NBD1 stabilization, the analyst tells investors in a research note. The firm says the company “has checked all the boxes one would want to see” for a preclinical company in cystic fibrosis. It likes the stock risk/reward into 2026 proof-of-concept data.